Requirement 1: A method of treating cancer.This includes providing effective combination drugs for those in need, including (a) a small molecule CSF-1R inhibitor and (b) a dying antibody or a specific CD40 antigen binding part. Requirement 3: Method that meets Requirement 1.Cancer was selected from the pancreatic cancer group.Prostate cancer.Rectal cancer.Lung cancer, lung cancerLymphoma is not Hodgkin'sBreast cancer and melanoma Proposition 13: Approaches to dealing with any claim 1-12,In this case, CSF-1R small molecule inhibitors were selected from the AB-530 group.AC-708AC-710,AC-855,BLZ-3495DCC-3014,GW-2580,Ilorasertib,Masitinib,Nitrogen dioxidePLX 5622,PLX FK1,PLX-7486REDX-05182 and a formula compound (1),Or a whistleblowerHydrate.Tautoros or salt accepted for drug efficacy Proposition 15: Approaches to dealing with any claim 1-14,Among them, CSF-1R small molecule inhibitor is a formula compound (1).Or a whistleblowerHydrate.Tautoros or salt accepted for drug efficacy 11. Requirement 17: Method 16The formulation compound (1) manages its antigen before using the dying antibody or binding fragment.People who specialize in CD40 Requirement 18: Approach 17In this case, a formulation compound (1) is administered daily for one to thirty days, prior to the administration of the dying antibody or its antigen binding portion.People who specialize in CD40 Proposition 20: Approaches to dealing with any claim 16-19,Among them, formula (1) compound was applied quantitatively in the range of about 10 mg per day to about 600 mg per day.Where antibodies are dying or attached to fragments of this antigen,People who specialize in CD40It is managed about once a week and about every three months.Quantity in the range of about 1 mg/kg to about 100 mg/kg.Reivindicación 1: Un método para tratar un cáncer, que comprende administrar a un sujeto con necesidad de este una cantidad terapéuticamente efectiva de coterapia que comprende (a) un inhibidor de CSF-1R de molécula pequeña y (b) u
